ArticleTrials2025

Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial.

Erik Ehinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.